Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCK1 | P35558 | 12/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KCNJ6 | P48051 | 3/20 | 0.35 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.35 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978661 | 0.85 | PCK1 (0.53) | PCK1HTT | |
| SCHEMBL3978029 | 0.84 | PCK1 (0.41) | PCK1POLBKCNJ6KCNJ5KCNJ3 | |
| SCHEMBL3977690 | 0.83 | PCK1 (0.52) | PCK1HTT | |
| SCHEMBL3982176 | 0.83 | PCK1 (0.50) | PCK1HTT | |
| SCHEMBL3981170 | 0.82 | PCK1 (0.56) | PCK1LMNA | |
| SCHEMBL3978657 | 0.80 | PCK1 (0.51) | PCK1 | |
| SCHEMBL6427176 | 0.80 | PCK1 (0.45) | PCK1ALDH1A1HTT | |
| SCHEMBL4614243 | 0.80 | PCK1 (0.53) | PCK1 | |
| SCHEMBL4613199 | 0.80 | PCK1 (0.47) | PCK1ALDH1A1 | |
| SCHEMBL3978815 | 0.79 | MTOR (0.41) | PCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135475-B2 | Antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | claimed |
| EP-1515972-B1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-05-13 | — | — | EP | disclosed |
| US-7135475-B2 | Antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040014766-A1 | Amide substituted xanthine derivatives | HOFFMANN-LA ROCHE INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014766-A1 | Amide substituted xanthine derivatives | GYS2, GLS2, PYGL | PCK1 14/4885P2RX7 1472/4885POLB 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.